# Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

> **NCT03719105** · EARLY_PHASE1 · RECRUITING · sponsor: **New York Medical College** · enrollment: 40 (estimated)

## Conditions studied

- NK-Cell Lymphoma
- NK-Cell Leukemia
- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** pralatraxate,
- **DRUG:** Ifosfamide
- **DRUG:** Dexamethasone
- **DRUG:** Etoposide
- **DRUG:** calaspargase pegol
- **DRUG:** cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone
- **DRUG:** Brentuximab Vedotin

## Key facts

- **NCT ID:** NCT03719105
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-03-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03719105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03719105, "Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03719105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*